Drugs / Ublituximab + TGR-1202
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02006485 | Dec 2013 → Oct 2019 | B-cell chronic lymphocytic leukemia | TG Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ublituximab + TGR-1202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02006485 ↗ |
| Action | Inhibit | “umbralisib, a PI3K-δ inhibitor” PMID 31558467 ↗ Nov 2019 |
| Route | Oral | “Umbralisib was given orally once daily at 800 or 1200 mg (initial formulation) or 400 to 1200 mg (micronized formulation)” PMID 31558467 ↗ Nov 2019 |